Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | -63.24%196.46M | -25.68%200.27M | -25.68%200.27M | 79.56%318.48M | 21.25%244.66M | 78.43%534.4M | 4.68%269.47M | 4.68%269.47M | -74.98%177.37M | -84.96%201.78M |
-Cash and cash equivalents | -63.24%196.46M | -25.68%200.27M | -25.68%200.27M | 79.56%318.48M | 21.25%244.66M | 78.43%534.4M | 4.68%269.47M | 4.68%269.47M | -74.98%177.37M | -84.96%201.78M |
Receivables | --0 | --0 | --0 | 20.22%96.05M | 6.72%90.63M | 12.01%93.85M | 2.39%87.65M | 2.39%87.65M | -16.63%79.89M | -1.73%84.92M |
-Other receivables | ---- | ---- | ---- | 20.22%96.05M | 6.72%90.63M | 12.01%93.85M | 2.39%87.65M | 2.39%87.65M | 5.88%79.89M | 24.49%84.92M |
Net loan | 10.84%6.27B | 7.26%5.97B | 7.26%5.97B | 10.04%5.83B | 13.36%5.78B | 17.83%5.66B | 16.08%5.57B | 16.08%5.57B | 15.90%5.3B | 17.61%5.1B |
-Gross loan | 10.56%6.34B | 7.25%6.05B | 7.25%6.05B | 10.12%5.91B | 13.37%5.86B | 17.91%5.74B | 16.25%5.64B | 16.25%5.64B | 16.02%5.37B | 17.76%5.17B |
-Allowance for loans and lease losses | 15.83%67.8M | 9.16%63.27M | 9.16%63.27M | 19.49%62.49M | 16.18%60.01M | 22.59%58.54M | 29.17%57.97M | 29.17%57.97M | 22.94%52.3M | 27.42%51.65M |
-Unearned income | ---- | 1.43%-16.97M | 1.43%-16.97M | -4.20%-16.39M | -7.06%-16.64M | -26.82%-16.91M | -32.71%-17.22M | -32.71%-17.22M | -36.53%-15.73M | -42.13%-15.54M |
Securities and investments | -3.83%954.8M | -2.55%946.39M | -2.55%946.39M | 3.75%981.21M | 1.14%982.82M | 1.84%992.82M | -0.94%971.16M | -0.94%971.16M | -1.91%945.77M | -4.34%971.79M |
-Available for sale securities | -7.19%32.28M | -4.26%480.88M | -4.26%480.88M | -14.13%31.8M | -4.65%28.71M | 19.18%34.78M | 6.89%502.3M | 6.89%502.3M | 89.79%37.03M | 54.68%30.11M |
-Held to maturity securities | -13.31%398.97M | -14.98%398.62M | -14.98%398.62M | -8.44%438.45M | -12.85%449.37M | -8.23%460.25M | -8.14%468.86M | -8.14%468.86M | -8.15%478.89M | -2.85%515.61M |
-Short term investments | 5.17%523.54M | --66.89M | --66.89M | 18.87%510.97M | 18.47%504.75M | 12.07%497.79M | --0 | --0 | 1.56%429.85M | -8.50%426.07M |
Other assets | 11.13%190.72M | 6.21%183.29M | 6.21%183.29M | -2.89%173M | 1.70%168.6M | 16.06%171.61M | 16.34%172.57M | 16.34%172.57M | --178.15M | --165.77M |
Total assets | 2.19%7.62B | 3.30%7.3B | 3.30%7.3B | 10.77%7.4B | 11.40%7.27B | 18.12%7.45B | 12.77%7.07B | 12.77%7.07B | 4.07%6.68B | -5.02%6.52B |
Liabilities | ||||||||||
Total deposits | 3.39%6.45B | 4.28%5.98B | 4.28%5.98B | 13.55%6.27B | 16.66%6.17B | 21.55%6.24B | 8.70%5.74B | 8.70%5.74B | -3.66%5.52B | -14.40%5.29B |
Federal funds purchased and securities sold under agreement to repurchase | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --243M |
Long term debt and capital lease obligation | -25.80%302.4M | -16.31%457.44M | -16.31%457.44M | -29.00%257.48M | 24.01%257.51M | 1.21%407.55M | 112.08%546.59M | 112.08%546.59M | 1,247.43%362.62M | 548.03%207.66M |
-Long term debt | -25.80%302.4M | -16.31%457.44M | -16.31%457.44M | -29.00%257.48M | 24.01%257.51M | 1.21%407.55M | 112.08%546.59M | 112.08%546.59M | 1,247.43%362.62M | 548.03%207.66M |
Preferred securities outside stock equity | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M | 0.00%20.62M |
Other liabilities | -6.99%106.14M | 5.51%109.89M | 5.51%109.89M | -2.41%140.16M | -11.09%125.39M | -22.37%114.12M | -22.95%104.15M | -22.95%104.15M | 1,428.67%143.62M | 499.36%141.04M |
Total liabilities | 1.45%6.88B | 2.53%6.57B | 2.53%6.57B | 10.58%6.69B | 11.39%6.57B | 18.90%6.78B | 12.60%6.41B | 12.60%6.41B | 3.57%6.05B | -6.23%5.9B |
Shareholders'equity | ||||||||||
Share capital | 0.89%113K | 0.90%112K | 0.90%112K | 1.82%112K | 1.82%112K | 0.00%112K | 1.83%111K | 1.83%111K | 0.92%110K | 0.92%110K |
-common stock | 0.89%113K | 0.90%112K | 0.90%112K | 1.82%112K | 1.82%112K | 0.00%112K | 1.83%111K | 1.83%111K | 0.92%110K | 0.92%110K |
Paid-in capital | 1.39%398.82M | 1.09%400.19M | 1.09%400.19M | 1.12%397.96M | 0.71%395.52M | -0.20%393.34M | 1.69%395.87M | 1.69%395.87M | 1.58%393.54M | 1.91%392.74M |
Retained earnings | 20.12%399.02M | 21.10%382.66M | 21.10%382.66M | 19.85%361.24M | 24.93%348.98M | 25.93%332.18M | 31.21%315.98M | 31.21%315.98M | 21.27%301.41M | 24.93%279.34M |
Less: Treasury stock | --12.94M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Gains losses not affecting retained earnings | 9.45%-47.17M | -0.37%-53.13M | -0.37%-53.13M | 26.64%-44.13M | -2.52%-52.21M | -3.91%-52.09M | 2.51%-52.94M | 2.51%-52.94M | -11.75%-60.15M | -46.46%-50.92M |
Total stockholders'equity | 9.55%737.85M | 10.74%729.83M | 10.74%729.83M | 12.64%715.19M | 11.45%692.4M | 10.80%673.54M | 14.43%659.02M | 14.43%659.02M | 9.05%634.91M | 8.18%621.28M |
Total equity | 9.55%737.85M | 10.74%729.83M | 10.74%729.83M | 12.64%715.19M | 11.45%692.4M | 10.80%673.54M | 14.43%659.02M | 14.43%659.02M | 9.05%634.91M | 8.18%621.28M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |